Oncology
Advanced Gynecological Malignancies
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Advanced Gynecological Malignancies is an early-stage landscape with 0 programs across 1 company. The most active players are BioRay Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
2
clinical trials
Completed1 · 50%
Not yet recruiting1 · 50%
Clinical Trials
Trial Activity
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Completed·—·Phase 1·NCT01065662·11 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)